The Discounted Cash Flow (DCF) model is the gold standard of company valuation. It is the method used by Goldman Sachs analysts building equity research reports, by private equity firms valuing acquisition targets, and by Warren Buffett and Howard Marks when assessing whether a business is worth buying. Its central principle is elegant and intuitive: a company is worth the present value of all the cash flows it will ever generate, discounted back to today at a rate that reflects the riskiness of those cash flows.
Everything else in investing — P/E ratios, EV/EBITDA multiples, price-to-book — is a shortcut for a DCF. When you pay 20x earnings for a stock, you are implicitly making assumptions about future growth rates, margins, and the appropriate discount rate. The DCF makes those assumptions explicit, which is precisely what makes it so powerful and so uncomfortable: it forces you to state and defend your assumptions rather than hiding behind a simple multiple.
This guide explains Fintiq's three-stage DCF model in full detail: every assumption, every formula step, and how to interpret the outputs to make better investment decisions.
The DCF framework forces you to think like a business owner rather than a stock market speculator. The question it asks is: "What is this business actually worth?" — not "Where will the share price go tomorrow?" This distinction matters enormously for long-term investment returns.
Charlie Munger famously said: "All intelligent investing is value investing — acquiring more than you are paying for." The DCF is the formal apparatus for answering the question of what you are getting for what you are paying. A stock trading at £10 is cheap if the intrinsic value is £18 and expensive if the intrinsic value is £6. The price tells you nothing without the value.
Fintiq uses a three-stage DCF structure that mirrors professional investment bank models. The three stages reflect the natural evolution of a company's growth trajectory over time:
The period where your conviction is highest. You have the most visibility into the company's near-term prospects: analyst guidance, management commentary, recent contract wins, product pipelines, and competitive dynamics. In Stage 1, you set revenue growth rates and operating margins explicitly for each year.
The period where growth and margins gradually converge toward industry averages or long-run sustainable levels. Most businesses cannot sustain above-average growth and margins indefinitely — competition, capital allocation, and market saturation all exert downward pressure. Stage 2 captures this mean reversion, with growth and margins interpolating between your Stage 1 estimates and the long-run steady state.
The period extending from Year 8 to infinity, captured as a single "terminal value" using the Gordon Growth Model. The terminal value assumes the company has reached a steady state: a constant long-run growth rate applied indefinitely. This is the most sensitive part of the model — the terminal value often represents 60-80% of the total estimated enterprise value.
WACC is the discount rate applied to future cash flows. It represents the minimum return that investors (both debt holders and equity holders) require from the company. Cash flows discounted at a higher WACC are worth less today; discounted at a lower WACC, they are worth more. WACC is the single most sensitive assumption in the entire model.
Typical WACC ranges by company type:
| Company Type | Typical WACC Range | Examples |
|---|---|---|
| Blue-chip defensive | 7% - 9% | Unilever, National Grid, AstraZeneca |
| Established growth | 9% - 11% | RELX, Rightmove, Games Workshop |
| Cyclical/financial | 10% - 12% | Banks, miners, energy |
| High-risk / small-cap | 12% - 16% | AIM stocks, early-stage businesses |
Sensitivity warning: Getting the WACC wrong by just 2 percentage points typically changes the intrinsic value estimate by 30-40%. Always run your DCF with a range of WACC assumptions (the sensitivity table in Fintiq) rather than relying on a single number.
The expected rate at which the company's revenues will grow each year. In Fintiq, you set this explicitly for Stage 1 (Years 1-3) and the model blends it toward a lower medium-term rate in Stage 2. Best practice is to use the lower of:
Never simply extrapolate recent strong growth indefinitely. AstraZeneca may be growing revenues at 15% currently driven by oncology blockbusters, but it is appropriate to fade that to 5-8% in Stage 2 as the patent cycle matures. Good DCF practice is conservative on growth: it is better to be pleasantly surprised than to build a model on blue-sky assumptions.
Operating margin is Operating Profit divided by Revenue. It represents the percentage of revenue that converts to operating profit before interest and tax. Different sectors have very different structural margin profiles:
| Sector | Typical Operating Margin | Drivers |
|---|---|---|
| Pharmaceuticals / Biotech | 25% - 40% | Patent-protected pricing, high R&D cost base |
| Software / SaaS | 20% - 35% | High gross margins, scalable distribution |
| Professional services | 12% - 20% | Labour-intensive, billing rate leverage |
| Energy / Mining | 10% - 25% | Commodity price exposure, high capital costs |
| Consumer staples | 8% - 15% | Volume-driven, brand pricing, distribution costs |
| Retail | 3% - 8% | High volume, low margins, working capital intensive |
| Banks | N/A (use ROE) | Banks require different valuation approaches |
Margins mean-revert over time. Unusually high margins attract competition that erodes them; unusually low margins eventually attract capital exit that allows survivors to recover pricing power. Your Stage 2 margin assumption should converge toward the sector average unless you have a specific and sustainable reason to believe the company can sustain above-average margins indefinitely (e.g., a genuine monopoly or regulatory moat).
The assumed perpetual growth rate of free cash flows from Year 8 onwards. This is typically set equal to long-run nominal GDP growth: 2-3% for a UK or European company, 2.5-3.5% for a globally diversified business.
Never use a terminal growth rate above 4%. Doing so implies the company will grow faster than the global economy indefinitely — meaning it will eventually become larger than the entire economy. This is mathematically impossible. Even if you believe strongly in a company's long-run prospects, the terminal growth rate should remain conservative. The terminal growth rate has an enormous impact on the terminal value because of the perpetuity formula: even a 0.5% change in terminal growth can alter the overall valuation by 15-20%.
Total borrowings minus cash and cash equivalents. The DCF model calculates Enterprise Value (the total value of the business to all capital providers). To convert Enterprise Value to Equity Value (the value belonging to shareholders), you subtract net debt.
A company with £2 billion Enterprise Value and £500 million net debt has an equity value of £1.5 billion. A company with net cash (negative net debt) of £300 million has an equity value of Enterprise Value + £300 million. This step is often overlooked by retail investors, leading to significant errors in per-share valuation.
The number of shares in issue, used to convert total equity value to intrinsic value per share. Use the diluted share count, which includes shares that could be created through exercise of options, convertible bonds, or warrants. Using the undiluted share count overstates the per-share intrinsic value because it ignores the dilution effect of these instruments. Fintiq pulls the diluted share count automatically from the company's latest annual report.
Benjamin Graham's conservative floor value for a stock, calculated as:
The Graham Number is deliberately conservative — it is a screening tool, not a precise valuation. Many high-quality companies trade permanently above their Graham Number because of their superior earnings power and moat. Use it as a lower-bound sanity check rather than a target price.
A relative valuation method that multiplies the company's earnings per share by the average P/E ratio of its sector peers:
Fintiq averages the three valuation methods — DCF intrinsic value, Graham Number, and Industry P/E — to produce a consensus estimate of fair value. This multi-method approach is more robust than any single method: each captures different aspects of value and has different sensitivities to assumptions. The consensus estimate, combined with the current market price, gives you the implied upside or downside to fair value.
Because the DCF is highly sensitive to its assumptions — particularly WACC and terminal growth rate — Fintiq automatically generates a sensitivity table showing how the intrinsic value changes across a range of WACC and growth rate combinations.
The sensitivity table tells you whether the current price is attractive across a range of realistic scenarios, not just your central estimate. A stock that looks cheap under your base case but collapses under even slightly conservative assumptions is far more dangerous than one that looks cheap across the entire sensitivity range.
Use Fintiq's free tools to screen stocks, run Monte Carlo simulations, and optimise your portfolio.
Launch Fintiq Free →